The primary amyloidosis comprise a group of diseases with an underlying clonal plasma cell dyscrasia. These diseases are classified by the type of amyloidogenic protein involved and by the distribution of amyloid deposits. In systemic amyloidosis, the unnatural protein is produced at a site that is remote from the site(s) of deposition, whereas, in localized disease, the amyloid light chain protein is produced at the site of deposition.
Primary or amyloid light chain amyloidosis (AL), the most common type of systemic amyloidosis, can cause organ dysfunction, most frequently in the kidneys, heart, and liver, although the central nervous system and brain may be affected.
HCT involves the intravenous (IV) infusion of allogeneic (donor) or autologous stem cells to reestablish hematopoietic function in individuals whose bone marrow or immune system is damaged or defective. They can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after delivery of neonates.